Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - EPIX Medical, Inc. (NasdaqNM:EPIX)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Financials | Reports
Location
71 Rogers Street
Cambridge, MA 02142
Phone: (617) 250-6000
Fax: (617) 250-6031
Email: info@epixmed.com
Employees (last reported count): 83
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Free Annual Report
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 39%
·Institutional: 38% (63% of float)
(51 institutions)
·Net Inst. Buying: 415.0K shares (+7.16%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
EPIX Medical, Inc. is engaged in the development of targeted contrast agents to both improve the capability and expand the use of magnetic resonance imaging (MRI) as a diagnostic tool for a variety of diseases. The Company's principal product under development, MS-325, is an injectable intravascular contrast agent designed for multiple cardiovascular imaging applications, including peripheral vascular disease and coronary artery disease. MS-325 is a small molecule that produces an MRI signal by containing gadolinium, a highly magnetically active element used for enhancing magnetic resonance images. This molecule is designed with the Company's proprietary technology to bind to albumin, a common blood protein. In MS-325 images using standard MRI techniques, the blood gives off a strong magnetic signal and appears bright against the dark background of surrounding tissue.
More from Market Guide: Expanded Business Description

Financial Summary
EPIX is a development stage company, engaged in the development of targeted contrast agents both to improve the capability and expand the use of magnetic resonance imaging (MRI) as a tool for diagnosing human diseases. For the six months ended 6/01, revenues rose 6% to $3.9 million. Net loss before acct'g change rose 10% to $10.1 million. Revenues reflect the development funding terms under the Schering agreement. Higher loss reflects higher clinical trial costs.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Christopher Gabrieli, 41
Chairman
--  --  
Michael Webb, 42
CEO, Sec., Director
$379K$48K
Stephen Knight, M.D., 40
Pres, COO
339K--  
Randall Lauffer, Ph.D., 43
Director and CSO
257K--  
Alan Carpenter, Ph.D., 48
Exec. VP of R&D
--  --  
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:EPIXAs of 31-Aug-2001
Price and Volume
52-Week Low
on 20-Dec-2000
$4.875
Recent Price$10.64 
52-Week High
on 19-Sep-2000
$16.125
Beta1.34 
Daily Volume (3-month avg)15.8K
Daily Volume (10-day avg)10.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y]
52-Week Change-29.1%
52-Week Change
relative to S&P500
-4.8%
Share-Related Items
Market Capitalization$150.6M
Shares Outstanding14.2M
Float8.60M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$0.38 
Earnings (ttm)-$1.78 
Earnings (mrq)-$0.37 
Sales (ttm)$0.53 
Cash (mrq)$1.66 
Valuation Ratios
Price/Book (mrq)28.16 
Price/EarningsN/A 
Price/Sales (ttm)20.00 
Income Statements
Sales (ttm)$7.16M
EBITDA (ttm)-$24.1M
Income available to common (ttm)-$23.9M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-78.49%
Return on Equity (ttm)-196.92%
Financial Strength
Current Ratio (mrq)2.18 
Debt/Equity (mrq)0.63 
Total Cash (mrq)$23.5M
Short Interest
As of 8-Aug-2001
Shares Short22.0K
Percent of Float0.3%
Shares Short
(Prior Month)
34.0K
Short Ratio2.00 
Daily Volume11.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.